NASDAQ: MBAICheck Cap Ltd Stock
$1.79-0.06 (-3.24%)
Updated Dec 23, 2025
MBAI Price
$1.79
Fair Value Price
-$0.02
Market Cap
$10.47M
52 Week Low
$0.60
52 Week High
$3.13
P/E
-0.42x
P/B
-7.22x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$25.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.26
Operating Cash Flow
-$8M
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MBAI Overview
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company was incorporated in 2004 and is based in Isfiya, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MBAI's potential to beat the market
- MBAI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
MBAI
RankedUnranked of 48
RankedUnranked of 48
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $17.41 | A | |
| $682.31 | B | |
| $230.83 | B |
Be the first to know about important MBAI news, forecast changes, insider trades & much more!
MBAI News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MBAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MBAI ($1.79) is overvalued by 7,798.33% relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MBAI ($1.79) is not significantly undervalued (7,798.33%) relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MBAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MBAI due diligence checks available for Premium users.
Valuation
MBAI fair value
Fair Value of MBAI stock based on Discounted Cash Flow (DCF)
Price
$1.79
Fair Value
-$0.02
Undervalued by
7,798.33%
MBAI ($1.79) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MBAI ($1.79) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MBAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MBAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.42x
Industry
22.43x
Market
44.94x
MBAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-7.22x
Industry
4.47x
MBAI's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MBAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$377.0k
Liabilities
$1.8M
Debt to equity
-1.26
MBAI's short-term liabilities ($1.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MBAI's short-term assets ($265.00k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MBAI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MBAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MBAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MBAI vs Diagnostic & Research Stocks
Check Cap Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.